Clarivate and CAPES Expand Landmark Partnership to Power Research and Innovation Across Brazil
LONDON, June 2, 2025 /CNW/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the renewal of its multi-year partnership with CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior), significantly expanding access to trusted Academia & Government and Life Sciences & Healthcare data across over 400 Brazilian institutions. As compared to the previous contract, the agreement increases institutional coverage by 57%, extending the reach of high-quality research tools to universities and research centers across Brazil — from major metropolitan areas to the country's most remote regions.
As a key agency under Brazil's Ministry of Education, CAPES plays a vital role in advancing postgraduate education, supporting high-level training, and fostering international scientific collaboration. A long-standing partner to CAPES, Clarivate began its collaboration with the agency in 2001, when the Web of Science became one of the first databases integrated into the CAPES Portal. This new agreement builds on that legacy, delivering enhanced access to solutions including Web of Science, Journal Citation Reports, Cortellis Drug Discovery Intelligence and Derwent Innovation Index.
By bringing together world-class data and insights from academic research and the life sciences and healthcare sectors, the agreement empowers researchers and practitioners at all levels — including scholars, policy advisors, biomedical scientists and healthcare professionals — to conduct innovative research, develop new treatments, improve patient care, and inform policy decisions. It provides broad access to critical information, advancing evidence-based discovery, education and decision-making across disciplines.
Matti Shem Tov, Chief Executive Officer, Clarivate, said:"This expanded partnership with CAPES is a powerful example of how strategic collaboration can accelerate research and innovation on a national scale. Brazil has made remarkable progress in advancing scientific excellence and global collaboration. We're proud to support this momentum by providing trusted data, insights, and technology to researchers across the country — from early discovery through impact assessment. Our shared commitment to expanding access and fostering innovation will continue to shape the future of research in Brazil and beyond."
Denise Pires de Carvalho, President, CAPES, said: "Brazil is experiencing a moment of growing scientific output beyond its major urban centers, with resources now being distributed in a more equitable and democratic way to boost productivity across all regions. This collaboration with Clarivate enables us to better understand the scientific production profile of Brazilian institutions and supports more informed investment decisions to reduce regional disparities, which remains a significant national challenge. Many researchers in the North, Northeast and Center-West have limited access to the resources needed to give visibility to their work and expanding that access can make a meaningful difference."
The renewed partnership reflects a shared commitment to democratizing access to critical scientific information and enabling data-driven research excellence. Through Web of Science, Journal Citation Reports, and Derwent Innovation Index, academic institutions and government agencies gain deeper visibility into global research trends, publication impact, and innovation pathways — supporting policy development, institutional benchmarking, and scholarly advancement.
Complementing these capabilities, expanded access to Cortellis Drug Discovery Intelligence equips Brazil's life sciences community — including postgraduate students, faculty, and biomedical researchers — with comprehensive insights across biology, pharmacology, and chemistry. From disease understanding and drug interactions to clinical studies and intellectual property, users can more efficiently navigate the full R&D lifecycle and accelerate decision-making in high-impact research areas.
By significantly expanding access to trusted research and innovation tools, this agreement supports CAPES' mission to reduce regional disparities and foster inclusive academic excellence. Institutions from across Brazil — from leading urban universities to those in underserved and remote regions — can now leverage high-quality data to strengthen postgraduate programs, accelerate innovation, and elevate the global visibility of Brazilian research.
Clarivate values its collaboration with CAPES on this initiative to help shape a more connected, informed and future-ready research ecosystem across Brazil, and stands as a resource for academic consortia worldwide seeking to expand access to trusted research, data and insights.
To learn more about this partnership and the solutions now available to CAPES institutions, visit here.
Notes to editors
According to the most recent Institute for Scientific Information G20 research and innovation scorecard:
Around 40% of Brazilian research output is internationally collaborative, with many strong bilateral partnerships with the United States. It also participates in larger collaborations involving the U.S., the U.K., Spain, Germany, and France. Compared with other internationally collaborative output, these partnerships are producing papers with above average impact.
Its research output shows a strong focus on Sustainable Development Goals (SDGs) Zero Hunger (SDG 2) and Life on Land (SDG 15), with impact for both around 0.7 to 0.8 times the world average.
More broadly, Brazilian research output has a strong focus on the Life Sciences, while its output in Medicine has impact around 1.1 times the world average.
Around 40% of output is published in open access (OA) journals, with their Humanities and Languages output 2.4 times more likely to be published in an OA journal than the G20 average.
About Clarivate
Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com
About Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) is a consortium dedicated to expanding and strengthening postgraduate studies in Brazil. It ensures the quality of academic programs while fostering the development of highly qualified professionals in research, teaching, and other strategic scientific fields.
Media contacts:
Clarivate
Catherine Daniel
Director, External Communications – Life Sciences & Healthcare
[email protected]
CAPES
João Mendes
Communications
[email protected]
SOURCE Clarivate Plc
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
GE Vernova's Q2 Electrifies Stock, What's Next For This Top Name?
If GE Vernova's (NYSE: GEV) latest earnings results are any indication, General Electric's corporate restructuring continues to look like a stroke of genius. On July 23, the energy equipment spin-out saw shares soar over 14% after reporting Q2 financials. As of the July 23 close, GE Vernova has provided a total return of nearly 92% in 2025. This makes it the second-best performing stock in the S&P 500 Index, behind only Palantir Technologies (NASDAQ: PLTR). Let's break down GE Vernova's Q2, which validates the bullish sentiment on the stock. Ultimately, we'll aim to answer whether investors should continue betting that the stock's huge run will continue or if it is time to take profits and look for opportunities elsewhere. GEV's Q2: This Energy Enabler Is Firing on All Cylinders In Q2, sales came in at $9.1 billion, equating to a growth rate of 11%. This figure was approximately $328 million higher than Wall Street analysts anticipated. Just as important were the increases in the company's orders and backlog, as these are strong indicators of future revenue. Orders rose by 4% to $12.4 billion, 1.4 times higher than the company's revenue in Q2. Meanwhile, GE Vernova's backlog grew 11.4% to $129 billion, 3.5 times higher than the company's expected revenue in 2025. These figures are positive signs for investors in the near and long term. Right now, sales are outpacing expectations. Orders remain substantially higher than revenues, indicating that revenue growth can continue at this pace in the near term. The company's backlog indicates that long-term revenue potential is increasing slightly faster than current revenue. This suggests that GE Vernova can maintain or even accelerate its revenue growth in the coming years. Beating sales expectations and margin improvements helped GE Vernova post earnings per share of $1.86, surpassing estimates of $1.63. Additionally, the firm increased the midpoint of its free cash flow guidance by $1 billion to $3.25 billion. This might be the most encouraging sign of all for investors. Bringing in more cash than it spends is the ultimate goal of any business, and GE Vernova is making robust progress. AI Energy Needs Are Driving Huge Wins for GEV's Natural Gas Solutions Diving further into the company's report helps explain what is driving GE Vernova's incredible success. The company's Power segment is by far its largest, accounting for around 53% of total revenue last quarter. In this segment, the company sells natural gas turbines and provides servicing. Power also offers nuclear, hydroelectric, and steam power equipment and services. Orders in Power rose dramatically by 44% last quarter. Natural gas orders nearly tripled versus Q2 2024, driving this. Utility companies must scale up their electricity generation capacity to keep up with surging demand due to artificial intelligence (AI). AI data centers need energy that is both reliable and clean. This is why so many hyperscale data center companies have signed agreements for nuclear energy. However, the availability of nuclear sites is dropping, and new sites can take a decade to build. Thus, reliable and relatively clean natural gas is a logical alternative for scaling up energy capacity. Given its leadership in natural gas turbines, GE Vernova is an ideal company for meeting the demand for AI energy here and now. GE Vernova is also working to design and build nuclear small modular reactors (SMRs). SMRs help get around the long construction times of large reactors but are still in the developmental phase. This positions the company to meet the longer-term interests of hyperscalers. Additionally, GE Vernova's scale likely gives it a competitive advantage over smaller SMR developers. GEV: Valuation Is Lofty, But So Are Its Long-Term Opportunities As of July 23, GE Vernova trades at a forward price-to-earnings (P/E) ratio of 80x. That number is likely to come down as analysts revise earnings estimates upward. However, it is still 60% above the firm's average forward P/E of 50x since April 2024. This suggests that shares could be highly overvalued. However, it's tough to argue with the company's long-term prospects, especially given the potential of its SMR business. At the same time, it's hard to say the stock's massive surge and ballooning forward P/E don't warrant taking some money off the table. Maintaining some exposure to this name while looking for cheaper opportunities elsewhere feels like a prudent balance for investors to strike. Where Should You Invest $1,000 Right Now? Before you make your next trade, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list. They believe these five stocks are the five best companies for investors to buy now...
Globe and Mail
3 hours ago
- Globe and Mail
1 Reason to Buy Visa (V)
Key Points Visa is a high-quality business whose shares rarely go on sale, but that might not discourage investors from owning the stock. The company's competitive position is supported by the presence of a powerful network effect. Stablecoins have an uphill battle to put a dent in Visa's business model. 10 stocks we like better than Visa › Visa (NYSE: V) is a dominant force in the financial services industry. It runs a leading payments platform that connects consumers, banks, and merchants across the globe. The business even finds itself in Warren Buffett-led Berkshire Hathaway 's portfolio. This financial stock trades close to all-time highs, and a valid argument can be made that the current valuation isn't cheap. But this is an outstanding company that still deserves a closer look. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Here's one reason investors should buy Visa. Visa's unassailable competitive position In fiscal 2024, Visa processed 233.8 billion transactions valued at a whopping $15.7 trillion. It currently has 4.8 billion active cards that are accepted at 150 million merchants around the world. That scale is unmatched, and it demonstrates just how formidable Visa's competitive position is, which is a key reason to scoop up shares. The business benefits from an extremely powerful network effect. As the number of merchants that accept Visa grows, it's more valuable to have a Visa card. The opposite is also true, with more cardholders creating more sales opportunities for merchants. The threat of stablecoins With the passing of the Genius Act, investors might start to worry about the threat that stablecoins pose to Visa's business model. As things stand today, there's no reason to be concerned. While merchants will test the waters in an effort to cut payment processing costs, the real question of whether or not consumers will make the jump. Favorable legislation passing doesn't necessarily mean there will be mass adoption of stablecoins. People love their credit cards and the perks and rewards they offer. And a company like Visa is so ingrained in our economy, with the network effect already mentioned, as well as its deep relationships with banks and other players in the financial services industry, that it's a monumental task to disrupt it. Visa should continue to dominate the payments landscape for the foreseeable future. Should you invest $1,000 in Visa right now? Before you buy stock in Visa, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Visa wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025
Globe and Mail
3 hours ago
- Globe and Mail
Is This Top Warren Buffett Stock a No-Brainer Buy Right Now?
Key Points As this is Berkshire's second-biggest position, Buffett has certainly found some traits he appreciates. This premium credit card brand boasts superb charge-off rates that are the envy of the industry. Shares of American Express have performed exceptionally well in recent years, creating valuation risk. 10 stocks we like better than American Express › There are dozens of companies in Berkshire Hathaway 's public equities portfolio. A lot of attention might go to Apple or Coca-Cola. However, investors need to pay attention to another business that's at the top of the list. Warren Buffett-led conglomerate Berkshire Hathaway owns 21.6% of the outstanding shares of this well-known financial services company. This stock has climbed a phenomenal 217% just in the past five years (as of July 23). Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » But is it a no-brainer buying opportunity today? Holding a strong position in the credit card industry The company that Berkshire has such a huge stake in is American Express (NYSE: AXP). The top Buffett stock's underlying business certainly possesses some very favorable characteristics. For starters, Amex has a wide economic moat. This is something the Oracle of Omaha appreciates. It indicates a company's ability to defend itself against competitive forces, supporting its durability. The American Express brand is a key asset for the business. Some of the company's credit cards are at the premium end of the market, holding a special status among consumers. Offering impressive rewards and perks while charging hefty annual fees attracts people with higher incomes. American Express also benefits from a powerful network effect, which is true for other card and payment platforms. As the number of merchant acceptance locations grows, so does the utility for cardholders. And with more cardholders, merchants find more value because there are more opportunities to generate sales. Another favorable trait is just how steady American Express' financial performance is. The economic backdrop recently hasn't been the smoothest, with concerns about tariffs making investors and executives jittery. But Amex continues to shine. During the second quarter, the financial giant reported a 9% year-over-year increase in revenue. This was driven by a 7% bump in spending. For all the talk about macroeconomic weakness leading to a possible recession, Amex is giving investors every reason to remain optimistic. The percentage of card members loans that are 30 days or more past due is significantly below the industry average. Net write-off rates also declined sequentially and compared to the second quarter of 2024. The company is extremely profitable, something Buffett likes. American Express generated $2.9 billion in net income in the second quarter. The leadership team uses the excess cash to buy back shares and pay a dividend. These are certainly investor-friendly capital allocation practices. Why investors should tread with caution Shares of Amex have been a huge market outperformer in recent years. As a result of this strong performance, the stock isn't cheap. The market is asking investors to pay a price-to-earnings (P/E) ratio of 21.5 to buy the stock. That's definitely not a bargain, as it's well above the trailing-three-year average multiple. But it's also not egregiously expensive. Investors who want to own high-quality companies for a long time should undoubtedly have American Express at least on their watch list. The business should continue to post solid revenue and earnings growth for the foreseeable future, while the brand presence and network effect help it maintain its competitive standing. These are wonderful qualities to focus on. But it's really anyone's guess what valuation multiple the stock will trade at five or 10 years down the road. This is a critical factor to think about. If the P/E ratio expands, it can add tremendous upside. On the other hand, paying too high of a multiple up front can create a headwind, as the P/E ratio could contract over time. At the current price, American Express is far from being a no-brainer stock to buy. Should you invest $1,000 in American Express right now? Before you buy stock in American Express, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and American Express wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025
